Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

264
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
264
Relative Risk01:12

Relative Risk

307
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
307
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

178
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
178
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

237
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
237
Hazard Ratio01:12

Hazard Ratio

222
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
222
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

359
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
359

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity.

Cancers·2026
Same author

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

CA: a cancer journal for clinicians·2026
Same author

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Modeling the age-specific incidence of mild cognitive impairment incorporating the time-varying relationship of Alzheimer's disease biomarkers over 28 years.

Journal of Alzheimer's disease : JAD·2025
Same author

Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.

Nature medicine·2025
Same author

Reply to: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
See all related articles

Related Experiment Video

Updated: Aug 30, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

Joint inference for competing risks data using multiple endpoints.

Jiyang Wen1, Chen Hu2, Mei-Cheng Wang1

  • 1Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Biometrics
|August 26, 2022
PubMed
Summary
This summary is machine-generated.

This study introduces methods for analyzing multiple cumulative incidence functions (CIFs) with competing risks, incorporating longitudinal data for weighted CIFs. These methods enhance understanding of complex clinical trial outcomes, such as COVID-19 hospitalization events.

Keywords:
COVID-19clinical trialcompeting riskscumulative incidencerestricted mean timeweighted survival time

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

353

Related Experiment Videos

Last Updated: Aug 30, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

353

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Epidemiology

Background:

  • Competing risks are common in clinical studies, with multiple events often having distinct clinical implications.
  • Simultaneous analysis of these events is crucial for accurate interpretation of trial effects.

Purpose of the Study:

  • To develop statistical methods for the joint analysis of multiple cumulative incidence functions (CIFs) in the presence of competing risks.
  • To incorporate longitudinal marker data for enhanced estimation and inference of weighted CIFs and related metrics.

Main Methods:

  • Development of estimation procedures and inferential properties for the joint use of multiple CIFs.
  • Incorporation of longitudinal marker information to derive weighted CIFs and associated metrics.
  • Application of proposed methods to a COVID-19 clinical trial dataset.

Main Results:

  • The study provides a framework for analyzing complex competing risks scenarios.
  • The methods allow for nuanced interpretation of clinical trial outcomes when multiple events of interest occur.
  • Demonstrated application in a COVID-19 trial highlights the practical utility of the proposed techniques.

Conclusions:

  • The developed methods offer robust tools for analyzing competing risks data in clinical research.
  • Joint analysis of multiple CIFs and weighted CIFs provides deeper insights into treatment effects.
  • This approach is particularly valuable for studies with events having differing clinical significance, like COVID-19 outcomes.